GSK signed early‑stage discovery agreements with Flagship Pioneering portfolio companies Profound Therapeutics and Quotient Therapeutics, validating proteomic and somatic‑genomics platforms for target discovery in respiratory and liver diseases. Flagship and its bioplatforms received up‑front commitments reported at $150 million to advance target identification and preclinical validation. Profound will apply its ProFoundry proteomics to proteins genetically linked to COPD and IPF; Quotient will use somatic genomics to uncover disease‑causal targets for COPD, IPF and metabolic dysfunction‑associated steatohepatitis. GSK holds exclusive options to advance programs into clinical development, and each selected program could trigger substantial milestone payments and royalties. The deals mirror Big Pharma’s growing strategy of outsourcing early discovery to specialized platform companies to accelerate target generation while sharing financial risk.